Pregabalin Capsule
Product Images NDC 80425-0170

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0170). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1

A line graph showing the percent of patients improved plotted against the percent improvement in pain from baseline. Four lines represent different treatment groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, with higher doses generally showing higher patient improvement percentages.*

FDA Label Image

Figure 10

A Kaplan-Meier curve comparing the estimated percentage of subjects without a specific event (LTR) over time in days for Pregabalin versus placebo groups. The graph shows a decline in the percentage over 180 days, with Pregabalin having a higher percentage of subjects without LTR than placebo.*

FDA Label Image

Figure 11

A line graph comparing the percent of subjects improved on the y-axis with percent improvement from baseline to Week 12 BOCF on the x-axis between Pregabalin and Placebo groups. The graph shows two curves, one representing Pregabalin with generally higher improvement percentages, and a lower curve representing Placebo, across the improvement range.*

FDA Label Image

Figure 12

A line graph showing the percent of subjects improved from baseline to week 16 of a study comparing Pregabalin (solid line) and placebo (dotted line). The x-axis represents percent improved, and the y-axis represents the percent of subjects improved, with Pregabalin showing consistently higher improvement compared to placebo.*

FDA Label Image

Figure 2

A line graph showing percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. It compares two groups: one receiving Pregabalin 100 mg three times a day and a placebo group, with the Pregabalin group consistently showing higher patient improvement percentages across pain improvement levels.*

FDA Label Image

Figure 3

A line graph illustrating the percent of patients improved versus percent improvement in pain from baseline. It compares five treatment groups: Pregabalin at 75 mg, 150 mg, and 300 mg taken two times a day, and a placebo group, showing response trends across different improvement thresholds.*

FDA Label Image

Figure 4

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating relative improvements in pain over the range of percent improvement.*

FDA Label Image

Figure 5

A line graph showing the percent of patients improved versus the percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph plots patient improvement percentages across increasing pain reduction levels.*

FDA Label Image

Figure 6

A bar chart comparing responder rates (%) across different treatment groups in two studies labeled E1 and E3. The X-axis shows treatment groups including placebo and various dosages labeled with mg/kg/day, and the Y-axis shows responder rates from 0% to 60%. The graph highlights statistically significant differences versus placebo noted by asterisks.*

FDA Label Image

Figure 7

A chart showing median percent change in seizure reduction from baseline versus dose in mg/day. The graph compares four study groups—E1 BID, E2 TID, E3 BID, and E3 TID—with statistical significance levels (p-values) indicated for dose effects compared to placebo across increasing dose levels up to 600 mg/day.*

FDA Label Image

Figure 9

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 600 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and Placebo, each represented with distinct line styles. The graph illustrates patient response rates across varying levels of pain improvement.*

FDA Label Image

Pregabalin 100mg Cap Qty 90 80425 0170

Label for Pregabalin 100 mg capsules, 90 count, labeled by Advanced Rx Pharmacy of Tennessee, LLC. The label includes a comparison note to LYRICA, lot number, expiration date of 7/31/2022, and storage instructions to keep at 20° to 25°C (68° to 77°F). Barcodes and product NDC 80425-0170-03 are also visible.*

FDA Label Image

Structure

Chemical structure diagram of pregabalin, showing its molecular composition with labeled functional groups including an amino group, a carboxyl group, and side chains characteristic of pregabalin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.